CN113101304A - Artificial pangolin scales substitute and preparation method thereof - Google Patents
Artificial pangolin scales substitute and preparation method thereof Download PDFInfo
- Publication number
- CN113101304A CN113101304A CN202110479773.2A CN202110479773A CN113101304A CN 113101304 A CN113101304 A CN 113101304A CN 202110479773 A CN202110479773 A CN 202110479773A CN 113101304 A CN113101304 A CN 113101304A
- Authority
- CN
- China
- Prior art keywords
- pangolin
- substitute
- scales
- artificial
- crocodile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000283966 Pholidota <mammal> Species 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 241000270722 Crocodylidae Species 0.000 claims abstract description 25
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 claims abstract description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 239000007787 solid Substances 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 10
- 238000005238 degreasing Methods 0.000 claims abstract description 6
- 239000003208 petroleum Substances 0.000 claims abstract description 6
- 238000004140 cleaning Methods 0.000 claims abstract description 4
- 239000003086 colorant Substances 0.000 claims abstract description 4
- 239000004576 sand Substances 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 5
- 239000005018 casein Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 241000283956 Manis Species 0.000 abstract description 3
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000006651 lactation Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
Abstract
The invention discloses an artificial pangolin substitute and a preparation method thereof, wherein the artificial pangolin substitute is prepared from crocodile scales and small peptide compounds in a weight ratio of 9: 1. The invention provides a preparation method of pangolin scales substitute, which comprises the following steps: (1) cleaning the artificially cultured crocodile scales, drying, putting into hot sand, frying until the colors are yellow and the scales are raised, and then crushing to obtain coarse crocodile scale powder; (2) extracting coarse powder of crocodile scale slices with ethanol, concentrating the extract, degreasing with petroleum ether, and drying to obtain a solid substance; (3) adding the solid into small peptide compound and medicinal adjuvants, and tabletting to obtain squama Manis substitute.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a formula of an artificial pangolin substitute and a preparation method thereof.
Background
The pangolin is named as \40717andthe resource of pangolin is rare, which belongs to the national animal protection and can not meet the market demand. At present, 40717jia is derived from squama of crocodile, and with the improvement of crocodile breeding technology, the breeding quantity of crocodile in China is more than one hundred thousand, and the medicine source is sufficient. And crocodile and pangolin are the same substances which are moved and flee, enter liver meridian and have curative effect on abdominal mass accumulation, and earlier researches show that the crocodile scall extract has better functions of promoting blood circulation, removing blood stasis, relieving swelling and expelling pus and can act on T cells to play a role in immunity. Meanwhile, the crocodile scales are safe and reliable to eat, and the crocodile scales (cultured) are developed into a pangolin substitute to meet the market demand.
Object of the Invention
The purpose of the invention is as follows: provides a pangolin substitute with the effects of reducing swelling, ulcerating carbuncle, dispelling wind, activating collaterals, clearing channels and promoting lactation. Thereby overcoming the problem of insufficient resources of the pangolin.
The technical scheme is as follows: in order to achieve the above purpose, the invention adopts the technical scheme that:
an artificial pangolin substitute is characterized by being prepared from the following raw materials in percentage by weight: 90% of crocodile scales and 10% of small peptide compounds.
Preferably, the artificial pangolin substitute comprises a small peptide complex comprising silk-casein-silk tetrapeptide and silk-casein-glycine-casein tetrapeptide in a mass ratio of 1: 1.
The preparation method of the artificial pangolin substitute comprises the following steps:
(1) cleaning the artificially cultured crocodile scales, drying, putting into hot sand, frying until the colors are yellow and the scales are raised, and then crushing to obtain coarse crocodile scale powder;
(2) taking coarse crocodile scale powder obtained in the step (1), extracting with ethanol with the volume concentration of 50%, concentrating an extracting solution, degreasing with petroleum ether, and drying to obtain a solid;
(3) adding the solid in the step (2) into a small peptide compound and a medicinal auxiliary material, and tabletting to obtain the pangolin scales substitute.
Preferably, the preparation method of the artificial pangolin scales substitute comprises the following steps (2): and (2) adding 8-20 times of ethanol with the volume concentration of 50-70% into the coarse crocodile scale powder obtained in the step (1), extracting for 1-3 times, each time for 30-120 minutes, combining the extracting solutions, concentrating, degreasing the concentrated solution for 1-3 times by using petroleum ether with the volume ratio of 1: 1-3 times, and drying to obtain a solid.
Preferably, in the above-mentioned method for preparing the artificial pangolin scales substitute, the weight ratio of the solid matter and the small peptide compound in the step (3) is 9: 1.
Advantageous effects
The invention can be used as a substitute of pangolin, replaces pangolin to be applied clinically, and has good effects of diminishing swelling, ulcerating carbuncle, removing wind, activating collaterals, clearing and promoting lactation. Can relieve the problem of insufficient market supply of squama Manis.
Detailed Description
Example 1
An artificial pangolin substitute which is prepared from the following raw materials in percentage by weight: 90% of crocodile scales and 10% of small peptide compounds. The small peptide compound consists of silk-casein-silk tetrapeptide and silk-casein-glycine-casein tetrapeptide in a mass ratio of 1: 1.
Example 2
The preparation method of the artificial pangolin substitute comprises the following steps:
(1) cleaning the artificially-cultured crocodile scales, drying, putting into hot sand, frying until the colors are yellow and the scales are raised, then crushing and sieving by a 40-mesh sieve to obtain coarse crocodile scale powder;
(2) and (2) adding 8-20 times of ethanol with the volume concentration of 50-70% into the coarse crocodile scale powder obtained in the step (1), extracting for 1-3 times, each time for 30-120 minutes, combining the extracting solutions, concentrating, degreasing the concentrated solution for 1-3 times by using petroleum ether with the volume ratio of 1: 1-3 times, and drying to obtain a solid.
(3) Adding the solid substance in the step (2) into a small peptide compound (the small peptide compound consists of silk-casein-silk tetrapeptide and silk-casein-glycine-casein tetrapeptide in a mass ratio of 1: 1) according to a mass ratio of 9:1, adding a proper amount of medicinal auxiliary materials of starch and cyclodextrin, and tabletting to obtain a pangolin substitute.
Example 3
1. Lactation test: 24 SD female rats are fed for 5 days and then are randomly divided into negative control groups, 10 squama Manis substitute high-dose groups (4g/kg) in example 1 are each group, the administration amount is 10mL/kg by intragastric administration at regular time each day, and the negative control groups are given with equal volume of pure water. On days 1, 3, 5, 8 and 15 of lactation, the amount of lactation of the mother mouse was calculated by measuring the weight of the young mouse.
2. The experimental method comprises the steps of separating the mother mouse and the young mouse for 3 hours, then re-combining the mother mouse and sucking for 1 hour, respectively weighing the litter weights of the young mouse before and after combining the cages, and calculating the lactation amount of the mother mouse according to the formula yield (g/pup/day) of 0.0322+0.0667(weight) +0.877 (gain/d).
3. The specific experimental results are shown in table 1:
TABLE 1 Effect of pangolin substitutes on lactation yield in mice (n-12, g)
P <0.05 in comparison with negative control group
Example 4
1. Anti-inflammatory assay: 60 rats with half male and female, randomly divided into 12 rats each, randomly divided into blank group, model group, pangolin substitute high and low dose group of example 1, prednisone acetate group, and each group administered by intragastric administration, wherein each group is administered by intragastric administration at fixed time each day with administration amount of 10mL/kg, 1 time each day, and continuously for 5 days. At 1h after the last administration, 50 μ L of 10% egg white was injected subcutaneously into the right hind foot sole of each rat except the blank group, and 50 μ L of physiological saline was injected into the blank group. After 30min, the heart is bled, centrifuged at 3000g/min for 20min, the supernatant is taken, and serum TNF-alpha, IL-2 and IL-6 are checked by ELISA method. The specific experimental results are shown in table 2: the pangolin scales substitute provided by the invention has better efficacy of reducing the contents of TNF-alpha and IL-6.
TABLE 2 Effect of the surrogate set on rat serum TNF-. alpha.IL-2 and IL-6 (n. 12, ng/L)
P <0.05 compared to blank group and P <0.05 compared to model group
Example 5
And (3) anticoagulation test: SD rats were collected in 40 groups, each half of male and female. After feeding for 5 days, the group is randomly divided into a control group and an aspirin group, and the high and low dose groups of the pangolin substitute in example 1 are 10 in each group, each group is subjected to intragastric administration at regular time each day, the administration amount is 10mL/kg, 1 time each day, and the control group is subjected to pure water with the same volume for 5 days continuously. Fasting is carried out for 24 hours before the last administration, 5% chloral hydrate is injected into the abdominal cavity for anesthesia 1 hour after the last administration, blood is taken from abdominal aorta, and the blood coagulation function is determined. The specific experimental results are shown in table 3:
TABLE 3 Effect of the artificial pangolin scales on the specific viscosity and clotting function of rat whole blood (n ═ 10)
P <0.05 in comparison to control group, # P <0.05 in comparison to aspirin group
The experimental results in Table 3 show that the artificial pangolin substitute provided by the invention has better anticoagulation effect.
The above embodiments are merely illustrative of the technical concept and features of the present invention, and the present invention is not limited thereto, and equivalent changes and modifications made according to the spirit of the present invention should be covered thereby.
Claims (5)
1. An artificial pangolin substitute is characterized by being prepared from the following raw materials in percentage by weight: 90% of crocodile scales and 10% of small peptide compounds.
2. The artificial pangolin substitute according to claim 1, wherein said small peptide complex consists of silk-casein-silk tetrapeptide and silk-casein-glycine-casein tetrapeptide in a mass ratio of 1: 1.
3. A process for the preparation of artificial pangolin substitute according to claim 1 or 2, characterized in that it comprises the following steps:
(1) cleaning the artificially cultured crocodile scales, drying, putting into hot sand, frying until the colors are yellow and the scales are raised, and then crushing to obtain coarse crocodile scale powder;
(2) taking coarse crocodile scale powder obtained in the step (1), extracting with ethanol, concentrating an extracting solution, degreasing with petroleum ether, and drying to obtain a solid substance;
(3) adding the solid in the step (2) into a small peptide compound and a medicinal auxiliary material, and tabletting to obtain the pangolin scales substitute.
4. The process for the preparation of artificial pangolin substitute according to claim 3, wherein step (2): and (2) adding 8-20 times of ethanol with the volume concentration of 50-70% into the coarse crocodile scale powder obtained in the step (1), extracting for 1-3 times, each time for 30-120 minutes, combining the extracting solutions, concentrating, degreasing the concentrated solution for 1-3 times by using petroleum ether with the volume ratio of 1: 1-3 times, and drying to obtain a solid.
5. The process for the preparation of artificial pangolin substitute according to claim 3, wherein the weight ratio of the solid matter and the small peptide compound in step (3) is 9: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110479773.2A CN113101304A (en) | 2021-04-30 | 2021-04-30 | Artificial pangolin scales substitute and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110479773.2A CN113101304A (en) | 2021-04-30 | 2021-04-30 | Artificial pangolin scales substitute and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113101304A true CN113101304A (en) | 2021-07-13 |
Family
ID=76720592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110479773.2A Pending CN113101304A (en) | 2021-04-30 | 2021-04-30 | Artificial pangolin scales substitute and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113101304A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4416871A (en) * | 1978-07-10 | 1983-11-22 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition by peptides of tolerance to and physical dependence on morphine |
| CN110279717A (en) * | 2019-06-13 | 2019-09-27 | 兰溪市立顺生物有限公司 | The preparation of crocodile first active principle and its anti-oxidant, anti-hepatic fibrosis application |
| CN111077244A (en) * | 2019-12-19 | 2020-04-28 | 苏州卫生职业技术学院 | Method for simultaneously measuring 4 water-soluble components in pangolin scales |
-
2021
- 2021-04-30 CN CN202110479773.2A patent/CN113101304A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4416871A (en) * | 1978-07-10 | 1983-11-22 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition by peptides of tolerance to and physical dependence on morphine |
| CN110279717A (en) * | 2019-06-13 | 2019-09-27 | 兰溪市立顺生物有限公司 | The preparation of crocodile first active principle and its anti-oxidant, anti-hepatic fibrosis application |
| CN111077244A (en) * | 2019-12-19 | 2020-04-28 | 苏州卫生职业技术学院 | Method for simultaneously measuring 4 water-soluble components in pangolin scales |
Non-Patent Citations (6)
| Title |
|---|
| OTSUKA Y, ARITA H, SAKAJI M等: "Investigation of the formation mechanism of proline-containing cyclic dipeptide from the linear peptide", 《BIOSCI BIOTECHNOL BIOCHEM》 * |
| OTSUKA Y, ARITA H, SAKAJI M等: "Investigation of the formation mechanism of proline-containing cyclic dipeptide from the linear peptide", 《BIOSCI BIOTECHNOL BIOCHEM》, vol. 83, no. 12, 29 August 2019 (2019-08-29) * |
| 刘逊,刘睿,赵呈雷等: "穿山甲高温砂炒炮制增效机制研究", 《中草药》 * |
| 刘逊,刘睿,赵呈雷等: "穿山甲高温砂炒炮制增效机制研究", 《中草药》, vol. 50, no. 7, 12 April 2019 (2019-04-12), pages 1 - 36 * |
| 刘逊,汪明志,吴芝园等: "不同炮制火候对砂炒穿山甲性状和环二肽类成分的影响", 《中药材》, vol. 42, no. 04, 25 April 2019 (2019-04-25), pages 11 - 22 * |
| 陈仁寿等: "《毒性本草类纂》", vol. 2020, 安徽大学出版社, pages: 1429 - 1430 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102153668B (en) | Anticancer Armillaria luteovirens polysaccharide and extraction process thereof | |
| US9028827B2 (en) | Compositions and methods for treating hepatitis virus infection | |
| JPH0321004B2 (en) | ||
| TWI598104B (en) | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
| CN104523755B (en) | A kind of blattaria active component and its preparation method and application | |
| CN104257696A (en) | Yeast powder for reducing and stabilizing blood sugar as well as preparation method and application of yeast powder | |
| CN102319256B (en) | Application of porphyra polysaccharide in preparing treatment medicament or prevention health-care product of kidney diseases | |
| CN101647816B (en) | Bionic enzymatic hydrolysate for animal skins and application thereof | |
| CN113101304A (en) | Artificial pangolin scales substitute and preparation method thereof | |
| CN102579559B (en) | Bauhinia championii ethyl acetate extract, n-butyl alcohol extract, and preparation methods and applications thereof | |
| CN105796587A (en) | Application of bamboo shaving polysaccharides in immunoregulation and tumor resisting | |
| CN105616462B (en) | Moringa oleifera extract for promoting intestinal growth and preparation method and application thereof | |
| CN101904856A (en) | Application of 1,6-diphosphofructose and derivative thereof in preparing animal medical health care products | |
| CN109294984B (en) | Lentinan capsule for efficiently amplifying NK cells in vivo and preparation method thereof | |
| WO2020248964A1 (en) | Use of rhus chinensis fruit in preparation of drugs for treatment and/or prevention of hepatic fibrosis | |
| CN1907432A (en) | Application of polysaccharide from the Gastrodia elata Blume in health caring stuff and medicine | |
| CN109364117B (en) | Anti-fatigue traditional Chinese medicine composition | |
| CN1368979A (en) | Hematopoietic arabinogalactan composition | |
| KR20020025433A (en) | Composition And Complex For Enhancing The Biological Function of Animals | |
| CN109078055B (en) | Isoferulic acid, traditional Chinese medicine extract containing isoferulic acid and application of cimicifuga foetida | |
| WO2018228431A1 (en) | Use of cimicifugae foetidae triterpenoid saponin extract, actein and deoxyactein | |
| TWI442920B (en) | Usage of toona sinensis extract for preparing drugs for decreasing weight or body fat | |
| CN101491518B (en) | Combination for treating tumor | |
| KR101772954B1 (en) | A anticancer pharmaceutical composition comprising herbal mixture extract of akebia quinata seed extract and panax ginseng, and lipopolysacharide | |
| CN116270634B (en) | Application of Zhongwuning in preparing medicine for preventing and treating liver diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210713 |